Cancer Causes & Control

, Volume 17, Issue 3, pp 251–256 | Cite as

Regular Use of Aspirin and Prostate Cancer Risk (United States)

  • Ravi J. Menezes
  • Helen Swede
  • Robert Niles
  • Kirsten B. MoysichEmail author
Original Paper


It has been hypothesized that aspirin and other nonsteroidal anti-inflammatory drugs can decrease the risk of developing prostate and other cancers, although observational studies have not been very conclusive. The current study examined the effects of regular aspirin use on prostate cancer risk in 1,029 patients with primary, incident cancer of the prostate and 1,029 hospital controls frequency-matched to cases by 5-year age group and period of questionnaire completion. Patients who reported use of aspirin for at least once a week for at least 6 months were classified as regular users, with others classified as non-users. Results indicate that regular aspirin use may not be associated with decreased prostate cancer risk [odds ratio (OR) 1.05, 95% confidence interval (CI) 0.89–1.25], frequency of use (OR for at least seven/week 0.91, 95% CI 0.73–1.13), duration of use (OR for at least 10 years of use 1.17 95% CI 0.93–1.46) or tablet years (defined as tablets per day x years of use). A similar lack of association was observed when analyses were performed examining stage of the cancer. These data suggest that aspirin use may not be associated with reduced risk of prostate cancer.


Aspirin Nonsteroidal anti-inflammatory drugs Prostate cancer 


  1. 1.
    Jemal, A, Murray, T, Ward, E, Samuels, A, Tiwari, RC, Ghafoor, A,  et al. 2005Cancer statistics, 2005CA Cancer J Clin551030PubMedGoogle Scholar
  2. 2.
    Bostwick, DG, Burke, HB, Djakiew, D, Euling, S, Ho, SM, Landolph, J,  et al. 2004Human prostate cancer risk factorsCancer10123712490PubMedGoogle Scholar
  3. 3.
    Thun, MJ, Henley, SJ, Patrono, C 2002Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issuesJ Natl Cancer Inst94252266PubMedGoogle Scholar
  4. 4.
    Kirschenbaum, A, Liu, X, Yao, S, Levine, AC 2001The role of cyclooxygenase-2 in prostate cancerUrology58127131PubMedGoogle Scholar
  5. 5.
    Gupta, S, Srivastava, M, Ahmad, N, Bostwick, DG, Mukhtar, H 2000Over-expression of cyclooxygenase-2 in human prostate adenocarcinomaProstate427378CrossRefPubMedGoogle Scholar
  6. 6.
    Yoshimura, R, Sano, H, Masuda, C, Kawamura, M, Tsubouchi, Y, Chargui, J,  et al. 2000Expression of cyclooxygenase-2 in prostate carcinomaCancer89589596CrossRefPubMedGoogle Scholar
  7. 7.
    Zha, S, Gage, WR, Sauvageot, J, Saria, EA, Putzi, MJ, Ewing, CM,  et al. 2001Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinomaCancer Res6186178623PubMedGoogle Scholar
  8. 8.
    Hussain, T, Gupta, S, Mukhtar, H 2003Cyclooxygenase-2 and prostate carcinogenesisCancer Lett191125135CrossRefPubMedGoogle Scholar
  9. 9.
    Pathak, SK, Sharma, RA, Steward, WP, Mellon, JK, Griffiths, TR, Gescher, AJ 2005Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategiesEur J Cancer416170CrossRefPubMedGoogle Scholar
  10. 10.
    Tsujii, M, DuBois, RN 1995Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2Cell83493501CrossRefPubMedGoogle Scholar
  11. 11.
    Tjandrawinata, RR, Hughes-Fulford, M 1997Up-regulation of cyclooxygenase-2 by product-prostaglandin E2Adv Exp Med Biol407163170PubMedGoogle Scholar
  12. 12.
    Liu, XH, Kirschenbaum, A, Lu, M, Yao, S, Klausner, A, Preston, C,  et al. 2002Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathwayBiochem Biophys Res Commun290249255PubMedGoogle Scholar
  13. 13.
    Thun, MJ, Namboodiri, MM, Calle, EE, Flanders, WD, Heath, CW,Jr 1993Aspirin use and risk of fatal cancerCancer Res5313221327PubMedGoogle Scholar
  14. 14.
    Schreinemachers, DM, Everson, RB 1994Aspirin use and lung, colon, and breast cancer incidence in a prospective studyEpidemiology5138146PubMedGoogle Scholar
  15. 15.
    Norrish, AE, Jackson, RT, McRae, CU 1998Non-steroidal anti-inflammatory drugs and prostate cancer progressionInt J Cancer77511555CrossRefPubMedGoogle Scholar
  16. 16.
    Langman, MJ, Cheng, KK, Gilman, EA, Lancashire, RJ 2000Effect of anti-inflammatory drugs on overall risk of common cancer: case–control study in general practice research databaseBMJ32016421646CrossRefPubMedGoogle Scholar
  17. 17.
    Nelson, JE, Harris, RE 2000Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case–control studyOncol Rep7169170PubMedGoogle Scholar
  18. 18.
    Habel, LA, Zhao, W, Stanford, JL 2002Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the USCancer Causes Control13427434CrossRefPubMedGoogle Scholar
  19. 19.
    Irani, J, Ravery, V, Pariente, JL, Chartier-Kastler, E, Lechevallier, E, Soulie, M,  et al. 2002Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer riskJ Urol16819851988CrossRefPubMedGoogle Scholar
  20. 20.
    Leitzmann, MF, Stampfer, MJ, Ma, J, Chan, JM, Colditz, GA, Willett, WC,  et al. 2002Aspirin use in relation to risk of prostate cancerCancer Epidemiol Biomarkers Prev1111081111PubMedGoogle Scholar
  21. 21.
    Roberts, RO, Jacobson, DJ, Girman, CJ, Rhodes, T, Lieber, MM, Jacobsen, SJ 2002A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancerMayo Clin Proc77219225PubMedGoogle Scholar
  22. 22.
    Perron, L, Bairati, I, Moore, L, Meyer, F 2003Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancerInt J Cancer106409415CrossRefPubMedGoogle Scholar
  23. 23.
    Garcia Rodriguez, LA, Gonzalez-Perez, A 2004Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancerCancer Epidemiol Biomarkers Prev13649653PubMedGoogle Scholar
  24. 24.
    Platz, EA, Rohrmann, S, Pearson, JD, Corrada, MM, Watson, DJ, Marzo, AM,  et al. 2005Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of AgingCancer Epidemiol Biomarkers Prev14390396CrossRefPubMedGoogle Scholar
  25. 25.
    Gonzalez-Perez, A, Garcia Rodriguez, LA, Lopez-Ridaura, R 2003Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysisBMC Cancer328PubMedGoogle Scholar
  26. 26.
    Mahmud, S, Franco, E, Aprikian, A 2004Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysisBr J Cancer909399CrossRefPubMedGoogle Scholar
  27. 27.
    Mettlin, C, Natarajan, N, Huben, R 1990Vasectomy and prostate cancer riskAm J Epidemiol13210561061 (discussion 1062–5)PubMedGoogle Scholar
  28. 28.
    Cornelison, TL, Natarajan, N, Piver, MS, Mettlin, CJ 1997Tubal ligation and the risk of ovarian carcinomaCancer Detect Prev2116PubMedGoogle Scholar
  29. 29.
    Moysich, KB, Mettlin, C, Piver, MS, Natarajan, N, Menezes, RJ, Swede, H 2001Regular use of analgesic drugs and ovarian cancer riskCancer Epidemiol Biomarkers Prev10903906PubMedGoogle Scholar
  30. 30.
    Suh, O, Mettlin, C, Petrelli, NJ 1993Aspirin use, cancer, and polyps of the large bowelCancer7211711177PubMedGoogle Scholar
  31. 31.
    Mettlin, C, Croghan, I, Natarajan, N, Lane, W 1990The association of age and familial risk in a case–control study of breast cancerAm J Epidemiol131973983PubMedGoogle Scholar
  32. 32.
    Mettlin, C 1989Milk drinking, other beverage habits, and lung cancer riskInt J Cancer43608612PubMedGoogle Scholar

Copyright information

© Springer-verlag 2006

Authors and Affiliations

  • Ravi J. Menezes
    • 1
  • Helen Swede
    • 2
  • Robert Niles
    • 1
  • Kirsten B. Moysich
    • 1
    Email author
  1. 1.Department of EpidemiologyRoswell Park Cancer InstituteBuffalo
  2. 2.Department of Epidemiology and Public HealthYale UniversityNew HavenUSA

Personalised recommendations